Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
EMvision Medical Devices Ltd. (EMV) vs. S&P 500 (SPY)
EMvision Medical Devices Ltd. Business Overview & Revenue Model
EMvision Medical Devices Ltd. Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 11.22M | 6.97M | 4.36M | 1.70M | 1.55M | Gross Profit |
| 11.22M | 6.63M | 4.12M | 1.58M | 1.55M | EBIT |
| -1.61M | -10.93M | -10.47M | -10.18M | -5.11M | EBITDA |
| -2.09M | -3.49M | -7.84M | -9.56M | 0.00 | Net Income Common Stockholders |
| -2.73M | -3.87M | -6.11M | -8.40M | -3.48M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 18.67M | 9.97M | 6.80M | 9.69M | 5.41M | Total Assets |
| 23.97M | 11.52M | 8.51M | 10.77M | 6.01M | Total Debt |
| 2.90M | 3.04M | 737.86K | 213.17K | 0.00 | Net Debt |
| -15.70M | -6.93M | -6.06M | -9.48M | -5.41M | Total Liabilities |
| 5.46M | 6.40M | 1.43M | 720.01K | 489.73K | Stockholders Equity |
| 18.52M | 5.12M | 7.08M | 10.05M | 5.52M |
| Cash Flow | Free Cash Flow | |||
| -6.29M | 646.86K | -3.97M | -4.62M | -3.26M | Operating Cash Flow |
| -5.99M | 834.15K | -3.78M | -4.49M | -3.26M | Investing Cash Flow |
| -302.41K | -187.29K | -191.12K | -127.25K | 0.00 | Financing Cash Flow |
| 15.00M | 2.52M | 1.08M | 8.90M | 4.28M |
EMvision Medical Devices Ltd. Technical Analysis
EMvision Medical Devices Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
48 Neutral | AU$166.76M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | $68.93M | ― | -51.08% | ― | 10.22% | -2.94% | |
39 Underperform | $29.22M | ― | -130.18% | ― | 3.37% | 47.32% | |
38 Underperform | AU$753.22M | ― | -38.95% | ― | ― | -16.77% |
EMvision Medical Devices Ltd. Corporate Events
EMvision Medical Devices Ltd announced the cessation of Geoff Pocock as a director, effective April 15, 2025. This change in leadership may impact the company’s strategic direction and stakeholder relations, as directors play a crucial role in guiding company operations and maintaining investor confidence.
EMVision Medical Devices Ltd has commenced a pivotal validation trial for its emu™ bedside brain scanner, aiming to secure FDA De Novo clearance. The trial, involving sites in Australia and the US, seeks to demonstrate the device’s effectiveness in detecting haemorrhages in stroke patients. With an enrolment period of 6-12 months, the trial will enroll 300 participants across six sites, with the goal of achieving a haemorrhage detection sensitivity and specificity of over 80%. This trial is critical for the company’s market positioning as it supports the FDA clearance process and sets the stage for the emu™ device to become a predicate for future products, such as a First Responder device. Concurrently, EMVision is conducting a Continuous Innovation Study to enhance its AI algorithms and device features, further solidifying its competitive edge in stroke diagnostics.
EMVision Medical Devices Ltd has successfully tested its First Responder Proof-of-Concept device in an aeromedical environment, marking a significant milestone in its development. The device, designed to enhance stroke and traumatic brain injury care, demonstrated resilience in challenging conditions and is part of a broader initiative involving collaborations with the Royal Flying Doctor Service and the Australian Stroke Alliance. This initiative aims to improve patient outcomes in rural and remote areas by providing timely neurodiagnostic capabilities, thereby addressing a critical unmet need in emergency medical care.
EMVision Medical Devices Ltd reported a significant increase in losses for the half-year ending December 31, 2024, with a net loss of $3.57 million compared to $112,607 in the previous period. The company’s income decreased by 55%, primarily due to lower grant income and R&D Tax Incentive rebates. Despite the financial challenges, EMVision continues to invest heavily in research and development, focusing on clinical trials and product development, supported by grants from the Australian Stroke Alliance and the Modern Manufacturing Initiative. The company’s net asset position remains strong, although cash reserves have decreased, and it continues to rely on non-dilutive funding to support its operations.
EMVision Medical Devices Ltd has received ethics approval from the US Institutional Review Board for its pivotal validation trial of the EMVision emu™ brain scanner, marking a significant milestone in its path towards FDA De Novo clearance. This approval, which classifies the study as non-significant risk, allows for rapid initiation and expedited execution of the trial, potentially strengthening the company’s position in the medical diagnostics industry and offering stakeholders promising advancements in neurodiagnostic solutions.
EMVision Medical Devices Ltd reported significant progress in its quarterly activities, particularly advancing the emu™ Bedside Scanner towards commercialization. The company achieved excellent results in its pre-validation EMView clinical trial, leading to preparations for the pivotal trial aimed at FDA clearance. The trial will involve up to 300 suspected stroke patients across multiple clinical sites, with market entry projected for CY26. Additionally, EMVision has developed a First Responder Proof-of-Concept brain scanner and is preparing for a feasibility study to integrate this device into pre-hospital care. These advancements position EMVision favorably in the neurodiagnostic space, enhancing its industry positioning and potential impact on stroke care.